Michael Gibney
Senior Editor & Writer | LinkedInMichael Gibney is a senior writer and editor for PharmaVoice. Before that, he covered the pharmaceutical industry as a healthcare reporter for three and a half years at S&P Global Market Intelligence and served as an editor at FiercePharma and FierceBiotech. Besides industry reporting, Michael has also covered science, wildlife and environmental issues as well as local news in Connecticut and Montana. A graduate of Bucknell University and the University of Missouri Journalism School, he is based in the Washington, D.C., area where you’ll find him hiking with two retired racing greyhounds, finding local breweries and grilling in the backyard.
256 articles by Michael Gibney
-
A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory
May 15, 2025 -
With the breakneck speed of cancer breakthroughs, oncologists feel left behind. Can Big Pharma chime in?
May 13, 2025 -
Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications
May 8, 2025 -
On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst
May 6, 2025 -
Can real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.
May 1, 2025 -
US backlash against mRNA vaccines could hinder scientific progress
April 29, 2025 -
Flagship’s latest venture reflects more than 25 years of leaping into the unknown
April 24, 2025 -
Beyond the drug: Closing the knowledge gap for injectable diabetes meds
April 22, 2025 -
Pharma’s capital allocation could shift as tariffs threaten an already fragile profit model
April 14, 2025 -
Trump’s tariff tirade and sudden calm keep Big Pharma on its toes
April 10, 2025 -
Her son’s DMD diagnosis shook her world. As a biotech CEO, it was also an epiphany for better rare disease R&D.
April 8, 2025 -
Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’
April 1, 2025 -
How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology
March 27, 2025 -
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
March 20, 2025 -
How non-traditional investors fuel up-and-coming biotechs when VC funding dries up
March 18, 2025 -
Lawmakers tease out pharma’s influence over RFK Jr. through probe into Mar-a-Lago meetings
March 13, 2025 -
Pricing transparency is in the spotlight — and that could be good news for drugmakers
March 11, 2025 -
The time is ripe for pharma M&A. Why are drugmakers holding out?
March 6, 2025 -
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach
March 4, 2025 -
AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration
Feb. 27, 2025 -
Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide
Feb. 25, 2025 -
Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO
Feb. 20, 2025 -
Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split
Feb. 13, 2025 -
Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma
Feb. 11, 2025 -
With uncertainty roiling Big Pharma, execs are placing lower-risk bets
Feb. 6, 2025